Trials / Completed
CompletedNCT00904592
A Study on Traditional Chinese Medicine (TCM) Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy
A Study on TCM Comprehensive Protocol of Prevention and Control in Diabetic Retinopathy
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 480 (actual)
- Sponsor
- Chengdu University of Traditional Chinese Medicine · Academic / Other
- Sex
- All
- Age
- 35 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
1. Title: A Study on TCM comprehensive protocol of Prevention and Control in Diabetic Retinopathy. 2. Objectives of study: To evaluate the Intervention effect of integrate control protocol on reducing the incidence rate of proliferative diabetic retinopathy, PRP and MVL. Then produce a high performance, optimize, convenient, applicable and demonstrated protocol of integrate control with Intervention of TCM and west medicine. 3. Study Type: Interventional 4. Study Design: Multi-center, Randomized, Blind (Subject, Investigator, Outcomes Assessor), Parallel Assignment, Positive controlled clinical study. 5. Sample size: 480 subjects , divided into test and control groups equally. 6. Primary endpoint: incidence rate of proliferative diabetic retinopathy, panretinal photocoagulation
Detailed description
1. Primary outcome: * proliferative diabetic retinopathy * panretinal photocoagulation 2. Secondary outcome: * Vision, Funduscopy, Fundus photograph * Fundus fluorescein angiography * Visual Electrophysiology:FERG、OPs、PVEP. * Optical coherence tomography. * Symptoms scores of TCM. * The M0S short-form-36 heaIth survey(SF-36). * Visual Function Questionnaire-25(VFQ-25).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Qi ming granula | Qi ming granula Usage:4.5g,po,tid. duration:12 months/ arise Endpoint Event |
| DRUG | Placebo Comparator | Control group: Basic therapy & placebo 1. Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education. 2. placebo,Usage: 4.5g,po,tid |
Timeline
- Start date
- 2008-09-01
- Primary completion
- 2010-10-01
- Completion
- 2011-04-01
- First posted
- 2009-05-19
- Last updated
- 2012-08-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00904592. Inclusion in this directory is not an endorsement.